explore -WSS

explore

author：explore 2025-08-12 11:27:55 - browse：4999

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

hotspot

knowledge

WSS

Affordable Connectivity Program vital to health care, experts say

Awakening the world to the whoosh: A patient's crusade

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Coercive sterilizations revealed by STAT prompt outrage

DeSantis talks Trump, trans issues and 'what wokeness is'

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Wikipedia

explore

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

California wildfire smoke linked to 52,000 early deaths, study says

Drug repurposing or repositioning? The language matters

Tocagen's brain cancer gene therapy trial continues. Investors worry

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Virtual Event: ASCO Recap, Live!

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How faith leaders like me can help address America's obesity epidemic

Malaria cases in Florida and Texas: Here’s what you need to know

Vir antibody drug aimed at influenza A fails in clinical trial

leisure time

Moderna says combo Covid

Cigna wins case to block Amy Bricker's move to CVS

Indian pharmaceutical industry in denial over drug

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

DeSantis talks Trump, trans issues and 'what wokeness is'

Stephen Quake on the Chan Zuckerberg quest to conquer disease

entertainment

hotspot

knowledge

focus